RemeGen Co., Ltd. (HKG:9995)

Hong Kong · Delayed Price · Currency is HKD

88.80

+2.60 (3.02%)

At close: Mar 13, 2026

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Biopharmaceutical Research,Service,Production and Sales	3.25B	1.72B	1.08B	772.11M	1.42B
Biopharmaceutical Research,Service,Production and Sales Growth	89.36%	58.54%	40.26%	-45.78%	-
Total	3.25B	1.72B	1.08B	772.11M	1.42B
Total Growth	89.36%	58.54%	40.26%	-45.78%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Mainland China	1.70B	-	-	131.31M
USA	12.69M	-	-	1.29B
Total	1.72B	-	-	1.42B

Source: S&P Global Market Intelligence.